F067 Skin Disease in Transplant Recipients and Immunosuppressed Patients
DESCRIPTION
Organ transplant recipients and other immunosuppressed patients have an increased risk of skin cancer development, progression, and death from skin cancer, as well as distinct presentations of inflammatory and infectious conditions. Dermatologists are uniquely positioned to care for these patients and optimize outcomes in the context of multidisciplinary care. This session will highlight key issues in the care of immunosuppressed patients, with a focus on prevention and management of multiple skin cancers, treatment of inflammatory and infectious skin disease, and recognition and mitigation of treatment fatigue. A patient representative will speak on the challenges of living with chronic skin disease.
LEARNING OBJECTIVES
Summarize recommendations for screening, detection and management of multiple skin cancers in transplant and immunosuppressed patients, recognizing the role of multidisciplinary care.
Prescribe topical and systemic therapy for treatment of precursor lesions and prevention of skin cancer in transplant and immunosuppressed patients.
Diagnose inflammatory and infectious skin disease in transplant and immunosuppressed patients, and identify factors that contribute to treatment fatigue and discontinuation in this population.
SCHEDULE
3:30 PM
Immunosuppression Overview
Sean Christensen, MD, PhD, FAAD
3:42 PM
Risk Assessment and Screening
Anokhi Jambusaria-Pahlajani, MD, MS, FAAD
3:54 PM
Field Therapy
Amrit Greene, MD, FAAD
4:06 PM
Q&A
4:10 PM
The Patient's Perspective
Sean Christensen, MD, PhD, FAAD, Peter Montesano
4:22 PM
Skin Cancer Exhaustion
Annika P Weinhammer, MD
4:34 PM
Inflammatory and Infectious Skin Disease
Lee Emerson Wheless, MD, PhD, FAAD
4:46 PM
Q&A
4:50 PM
Systemic Chemoprevention and Modification of Immunosuppression
Jake X Wang, MD, FAAD
5:02 PM
High-Risk SCC and Melanoma
Kristin Bibee, MD, PhD, FAAD
5:14 PM
Immunotherapy for Advanced Cancer
Nathalie C. Zeitouni, MD, FAAD
5:26 PM
Q&A
DIRECTOR
Sean Christensen, MD, PhD, FAAD
SPEAKERS
Kristin Bibee, MD, PhD, FAAD
Amrit Greene, MD, FAAD
Anokhi Jambusaria-Pahlajani, MD, MS, FAAD
Peter Montesano
Jake X Wang, MD, FAAD
Annika P Weinhammer, MD
Lee Emerson Wheless, MD, PhD, FAAD
Nathalie C. Zeitouni, MD, FAAD
HANDOUTS
DISCLOSURES
Kristin Bibee, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Sean Christensen, MD, PhD, FAAD
Castle Biosciences – Advisory Board(Honoraria); inhibitor therapeutics – Advisory Board(No Compensation Received); Sol-Gel Technologies – Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);
Amrit Greene, MD, FAAD
No financial relationships exist with ineligible companies.
Anokhi Jambusaria-Pahlajani, MD, MS, FAAD
Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);
Peter Montesano
No financial relationships exist with ineligible companies.
Jake X Wang, MD, FAAD
No financial relationships exist with ineligible companies.
Annika P Weinhammer, MD
No financial relationships exist with ineligible companies.
Lee Emerson Wheless, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Nathalie C. Zeitouni, MD, FAAD
Alpha Tau Medical – Investigator(Grants/Research Funding); Biofrontera AG – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Castle Biosciences – Investigator(Grants/Research Funding), Speaker(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Replimune – Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Investigator(Grants/Research Funding);